研究人员随机分配治疗:三联疗法与甲氨蝶呤(MTX)、柳氮磺胺吡啶(sulfasalazine)和羟氯喹(hydroxychloroquine),或者服用依那西普(etanercept)和甲氨蝶呤(MTX)。如果患者在24周内没有改善就换到另一组疗法。
基于9个网页-相关网页
Evidence for the safety of hydroxychloroquine was better vs chloroquine.
证据显示羟氯喹的安全性较氯喹高。
Of the 4905 patients included in this analysis, 1808 (37%) reported hydroxychloroquine use at some time during the observation period.
该研究分析的4905名患者,其中有1808名(37%)报告曾在观测期内某段时间使用过羟基氯喹。
Incidence rates per 1000 patient-years of observation were 8.9 for never-users of hydroxychloroquine and 5.2 for ever-users (p < 0.001).
未服用羟基氯喹的患者,糖尿病发病率为8.9/1000人年,而服过羟基氯喹的患者糖尿病发病率为5.2/1000人年(p < 0.001)。
应用推荐